Clinical Trial

A Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis (EMERGE)

Name: A Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis (EMERGE) — clinical trial record (NCT07647510)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

The purpose of this Phase 3 study is to demonstrate the efficacy, safety, and tolerability of claseprubart in participants with generalized myasthenia gravis (gMG).

Protocol Amendment History 1 change

critical Recruitment opened 2026-07-09

Trial Details

NCT Number	NCT07647510
Lead Sponsor	Dianthus Therapeutics
Conditions	Myasthenia Gravis, Generalized
Enrollment	195 participants
Start Date	2026-07
Primary Completion	2028-12 (estimated)
Study Completion	2031-09 (estimated)
Updated on ClinicalTrials.gov	2026-07-08